Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q03393

UPID:
PTPS_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q03393; B0YJ87; Q8WVG8

BACKGROUND:
The enzyme 6-pyruvoyl tetrahydrobiopterin synthase is essential for producing tetrahydrobiopterin, necessary for synthesizing key neurotransmitters. Its activity ensures the proper function of aromatic amino acid hydroxylases by transforming 7,8-dihydroneopterin triphosphate.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of 6-pyruvoyl tetrahydrobiopterin synthase could open doors to potential therapeutic strategies for treating Hyperphenylalaninemia, BH4-deficient, A, characterized by severe neurological symptoms due to impaired neurotransmitter synthesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.